REMINDER: Our focusIR Investor Webinar takes place TONIGHT with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShire Share News (SHP)

  • There is currently no data for SHP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Asian Shares Fall On Trump-Xi Agreement Scepticism, US Treasury Yields

Wed, 05th Dec 2018 08:44

CANBERA (Alliance News) - Asian stocks ended broadly lower on Wednesday amid concerns over trade and worrying signals of economic health after the difference between three- and five-year US Treasury yields dropped below zero.

Traders were sceptical around the Trump-Xi agreement announced over the weekend.

In China, traders paid little attention to encouraging services data. The benchmark Shanghai Composite index fell 16.15 points or 0.6% to 2,649.81 while Hong Kong's Hang Seng index tumbled 1.6% to close at 26,819.68.

The services sector in China continued to expand in November, and at an accelerated rate, the latest survey from Caixin revealed with a PMI score of 53.8. That beat expectations for 50.8, which would have been unchanged from the October reading.

Japanese shares fell after a plunge on Wall Street overnight on growth and trade concerns. The Nikkei average shed 116.72 points or 0.5% to finish at 21,919.33, while the broader Topix index closed 0.5% lower at 1,640.49.

China-focused shares ended lower, with Fanuc losing 3.4% and Rohm declining 1.5%. In the tech sector, Advantest slumped 4.6% and Tokyo Electron shed 1.8%.

Drug giant Takeda rose 1.1% after it received shareholder approval to acquire Irish pharmaceuticals firm Shire in a deal worth around USD60 billion.

On the economic front, the latest survey from Nikkei showed that the services sector in Japan continued to expand in November, albeit at a fractionally slower pace with a PMI score of 52.3, down from 52.4 in October.

Australian markets hit a two-week low before ending off their day's lows, dragged down by banks after official data showed the economy slowed more than expected in the third quarter of 2018.

Australia's GDP grew a seasonally adjusted 0.3% sequentially in the last quarter, missing expectations for an increase of 0.6% and down from 0.9% in the second quarter. On a yearly basis, GDP expanded 2.8% - again missing forecasts for 3.3% and down from 3.4% in the three months prior.

Another report from the Australian Industry Group revealed that the service sector in Australia continued to expand in November, and at a sharply faster rate.

The benchmark S&P/ASX 200 index ended down 44.70 points or 0.8% at 5,668.40 after losing 1.0% in the previous session. The broader All Ordinaries index dropped 48.40 points or 0.8% to 5,749.10

The big four banks fell between 0.7% and 1.2%. Mining heavyweights BHP Billiton and Rio Tinto rose modestly while energy majors Oil Search, Origin Energy, Beach Energy and Santos lost around 2% as oil resumed declines in Asian trade.

Rare earths miner Lynas Corp plummeted 22% after tough new conditions were announced for the company's license to operate in Malaysia.

Seoul stocks recovered some lost ground after hitting over one-week low earlier in the day. The benchmark Kospi fell over 1% before recouping some loss to end the session down 13.04 points or 0.6% at 2,101.31 on continued uncertainty over the Sino-US trade war.

New Zealand shares fell sharply as a flattening Treasury yield curve and doubts about the durability of the US-China trade war truce sparked worries about global growth.

The benchmark S&P/NZX 50 index dropped 84.23 points or 1.0% to finish at 8,781.53. Trade Me shares bucked the weak trend to end 3.1% higher after a second bidder emerged for the e-commerce leader.

Singapore's Straits Times index was down 0.6%. The country's private sector continued to expand in November, and at a faster rate, the latest survey from Nikkei showed with a PMI score of 53.8, up from 52.6 in October.

Overnight, US stocks tanked as the initial euphoria generated by a truce between the US and China over trade evaporated and an inverted yield curve in bond markets signalled an economic slowdown.

The Dow Jones Industrial Average tumbled 3.1%, the tech-heavy Nasdaq Composite plummeted 3.8% and the S&P 500 lost 3.2%.

More News
6 Sep 2019 07:54

UPDATE 1-Sumitomo Dainippon Pharma investing $3 bln in Swiss Roivant in overseas push

* Dainippon to buy 10% stake in Roivant and interests in 5 units * Schizophrenia treatment Latuda to lose US exclusivity in 2023 * Japan pharma firms grapple with declining Dainippon

Read more
14 Aug 2019 06:45

UPDATE 1-Germany's Stada 'very selective' on acquisitions - CEO Goldschmidt

FRANKFURT, Aug 14 (Reuters) - German generic drugmaker Stada will be careful about buying businesses and companies outright, and for now will focus mainly on striking production and development we

Read more
17 Jul 2019 17:55

Takeda kicks off sale of Western European drugs - sources

By Arno Schuetze and Pamela Barbaglia FRANKFURT/LONDON, July 17 (Reuters) - Japan's Takeda Pharmaceutical Co has reached out to prospective bidders for a portfolio of drugs for sale in

Read more
16 May 2019 18:35

Japan's Takeda expects binding offers for Latam business by end of May -sources

By Tatiana Bautzer SAO PAULO, May 16 (Reuters) - Japan's Takeda Pharmaceutical Co expects to receive binding offers for its Latin American business by the end of May, three sources of a

Read more
15 May 2019 08:05

Nikkei snaps 7-day losing streak helped by China's stimulus hopes

* Gains may be short-lived - analyst * Takeda Pharma, Nissan sink after earnings shock * Mitsubishi Estate jumps on share buyback, governance reform By Hideyuki Sano and Ayai

Read more
15 May 2019 04:04

Nikkei hobbled by trade worries, disappointing earnings

* Nikkei down slightly after 7 losing sessions * Uncertainties over U.S.-China standoff keep investors on edge * Takeda Pharma, Nissan sink after earnings shock * Mitsubishi -

Read more
14 May 2019 07:56

UPDATE 1-Japan's Takeda forecasts 193 bln yen annual operating loss on Shire deal

* 193 bln Y op loss forecast this yr vs 227.5 bln profit view of analysts * Shire acquisition made Takeda one of the world's most indebted drugmakers (Adds details of results, May 14 -

Read more
14 May 2019 07:39

Japan's Takeda expects annual loss on Shire deal

TOKYO, May 14 (Reuters) - Takeda Pharmaceutical Co forecast on Tuesday it would have an operating loss in the current financial year, as it books costs associated with the multibillion-dollar an a

Read more
9 May 2019 00:38

UPDATE 1-Novartis buys Takeda's dry eye drug for $3.4 bln

May 8 (Reuters) - Swiss drugmaker Novartis AG said on Wednesday it agreed to acquire Takeda Pharmaceutical Company Ltd's dry eye drug Xiidra for $3.4 billion, as well as potential milestone of

Read more
1 Feb 2019 06:07

Japan's Takeda posts 28 pct rise in Q3 operating profit

TOKYO, Feb 1 (Reuters) - Takeda Pharmaceutical Co Ltd on Friday posted a 27.9 percent rise in third-quarter operating profit, supported by strong sales of its drugs for bowel disease and multiple

Read more
22 Jan 2019 02:46

Nikkei dips as global growth concerns sap risk appetite

* IMF cuts global growth forecasts * Companies with big China exposure fall * Totech soars after raising earnings forecast By Ayai Tomisawa TOKYO, Jan 22 (Reuters) - in

Read more
8 Jan 2019 13:54

MARKET ANALYSIS: Optimism About Trade Talks May Generate Continued Buying Interest

WASHINGTON (Alliance News) - The major US index futures are pointing to a higher opening on Tuesday, with stocks likely to extend the strong upward move seen over the two previous about trade the

Read more
8 Jan 2019 08:58

Asian Shares Mixed Despite US-China Trade Deal Optimism

CANBERA (Alliance News) - Asian stocks ended mixed on Tuesday despite optimism over US-China trade talks as US officials held a second day of trade talks with Chinese counterparts in second day of

Read more
8 Jan 2019 07:39

Takeda takes control of Shire

(Sharecast News) - Takeda Pharmaceutical has taken full control of Shire after the legal particulars of its cash and share offer were completed.

Read more
7 Jan 2019 04:29

Takeda unlikely to sell OTC drug business -CEO

(Adds quote, other details) TOKYO, Jan 7 (Reuters) - Takeda Pharmaceutical is unlikely to sell its over-the-counter (OTC) drug business even amid pressure to improve its finances as it a a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.